Eli Lilly, Zepbound
The maker of blockbuster appetite-suppressing drugs Mounjaro and Zepbound is seeking to end a regulatory designation that has ...
1don MSN
The GLP-1 drug giant’s shares have surged this year. Eli Lilly could keep climbing thanks to strong demand for Mounjaro and ...
In a recent interview on CNBC, the company's CEO, David Ricks, was discussing the strong growth the business has been ...
Eli Lilly and Novo Nordisk compete in a handful of different markets. Novo Nordisk is scaling up its output and upgrading ...
Shares of Eli Lilly & Co. LLY shed 0.92% to $940.20 Thursday, on what proved to be an all-around mixed trading session for ...
4don MSN
Eli Lilly is offering 2.5-milligram and 5-milligram single-dose vials of Zepbound for $399 per month and $549 per month, ...
Eli Lilly is cutting the cost of certain weight loss drugs, with new single-dose vials costing less than other medications ...
We recently compiled a list of the Jim Cramer’s 10 Go-To Stocks for Success. In this article, we are going to take a look at ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results